Adding niraparib to abiraterone and prednisone prolongs rPFS in patients with mCSPC harboring HRR gene alterations.
mHSPC/mCSPC
Advertisement
Drs. Ong and Roy detail a multinational real-world analysis of the IRONMAN registry on the significance of PSA>0.2.
Drs. Swami and Ciuro discuss adoption of treatment intensification, barriers to guideline-concordant care, and more in mHSPC.
The approval of darolutamide by the FDA expands treatment options available for patients diagnosed with mCSPC.
Drs. Privé and Tagawa discuss the BULLSEYE trial, an analysis of Lutetium-177-PSMA-617 in oligometastatic HSPC.
Five-year ARCHES follow-up evaluates the overall surival benefit of enzalutamide + ADT in patients with mHSPC.
Researchers suggest that darolutamide may delay deterioration of quality of life in patients with mHSPC.
Researchers evaluated SBRT plus short-term hormonal therapy in oligometastatic HSPC, examining the tolerability and efficacy.
Researchers evaluated the addition of zoledronic acid to the standard treatment of enzalutamide and ADT.
Roundtable Discussions
The panel explores the the role of imaging, genomics, and patient factors in the management of mHSPC.
The panel goes in-depth on the use of testing and SBRT as metastasis-directed therapy in newly diagnosed prostate cancer.
The panel focuses on decision-making between AR antagonists and abiraterone, weighing factors such as reimbursement.
The panel zooms in on the use of radium, enzalutamide, and other therapeutic agents, touching on patient preference trials.
The panel highlights the limitations of conventional imaging in detecting disease progression at undetectable PSA levels.
Prostate Cancer Knowledge Hubs
Advertisement
Section Editor
Jordan Ciuro, MDAssistant Professor of Medicine & Medical Oncologist | Emory Winship Cancer Institute
Advertisement
Get the latest mHSPC research straight to your inbox.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.